Cell-free DNA diagnostics in transplantation utilizing next generation sequencing.
The use of Next Generation Sequencing (NGS) to interrogate cell-free DNA (cfDNA) as a transplant diagnostic provides a crucial step in improving the accuracy of post-transplant monitoring of allograft health. cfDNA interrogation provides a powerful, yet minimally invasive, biomarker for disease and tissue injury. cfDNA can be isolated from a variety of body fluids and analyzed using bioinformatics to unlock its origins. Furthermore, cfDNA characteristics can reveal the mechanisms and conditions under which it was generated and released. In transplantation, donor-derived cfDNA monitoring provides a tool for identifying active allograft injury at the time of transplant, infection, and rejection. Multiple detection and interrogation methods for cfDNA detection are now being evaluated for clinical validity and hold the promise to provide minimally invasive, quantitative, and reproducible measures of allograft injury across organ types.
Jackson, Annette M., Carly Amato-Menker, and Maria Bettinotti. “Cell-free DNA diagnostics in transplantation utilizing next generation sequencing.” Hum Immunol 82, no. 11 (November 2021): 850–58. https://doi.org/10.1016/j.humimm.2021.07.006.